As of Oct 20
| -0.30 / -5.88%|
The 8 analysts offering 12-month price forecasts for BioCryst Pharmaceuticals Inc have a median target of 9.50, with a high estimate of 15.00 and a low estimate of 4.00. The median estimate represents a +97.92% increase from the last price of 4.80.
The current consensus among 9 polled investment analysts is to Buy stock in BioCryst Pharmaceuticals Inc. This rating has held steady since October, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.